Company Overview
Ainos, Inc. operates as a dual-platform entity combining artificial intelligence and biotechnology capabilities, specifically utilizing its SmellTech platform to digitize scent data and its AI diagnostics and immune therapeutics initiatives. This operational model places the company within the Technology sector, specifically under the Scientific & Technical Instruments industry, where it leverages machine-readable data to convert invisible chemical signals into actionable insights. The organization employs 44 individuals and maintains a total market capitalization of $9.71M, reflecting a small-cap status typical for early-stage development firms in niche scientific fields. With annual revenue recorded at $113,037, the company's financial scale suggests it is currently in a resource-intensive phase of product development and market entry rather than mature commercialization. These metrics indicate that the firm is operating with a modest revenue base relative to its market cap, a common characteristic for technology companies investing heavily in R&D before achieving profitability.
Financial Health
The company reported total revenue of $113,037 for the trailing twelve months, yet it posted a net income loss of $14,956,726 and an EBITDA of $-9,556,894, revealing a significant divergence between top-line generation and bottom-line profitability. This substantial gap between revenue and net income highlights a cost structure dominated by expenses that far exceed current sales, which is typical for entities in the research and development phase. Despite the lack of profitability, the company generated $2,875 in free cash flow, providing a minimal but positive level of financial flexibility to cover immediate operational outflows without external financing. The gross margin stands at 82.7%, indicating that the core production or service delivery costs are relatively low compared to the revenue recognized, whereas the operating margin is -128481.4% and the profit margin is 0.0%, signaling that general and administrative expenses or other costs are disproportionately high relative to the small revenue base. On the liability side, the company holds $1.13M in cash against $11.00M in debt, resulting in a debt-to-equity ratio of 109.51, which characterizes the balance sheet as highly leveraged and reliant on equity or future capital raises to service obligations. The current ratio is 2.96, suggesting that the company possesses sufficient current assets to cover its short-term liabilities, although the high leverage creates a long-term liquidity risk. Return on Equity is -106.6% and Return on Assets is -33.1%, metrics that demonstrate that management is currently consuming equity and assets to fund operations rather than generating returns for shareholders.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of earnings, which implies that traditional earnings-based valuation methods are not applicable at this stage. Consequently, the price-to-book ratio serves as a primary valuation metric, standing at 0.66, which indicates that the market is currently valuing the company at less than one times its book value. The price-to-sales ratio is 85.86, a figure that is elevated and suggests the market is pricing in significant future growth expectations despite current losses. Additionally, the EV/EBITDA ratio is -1.73, further confirming that the company's enterprise value is negative relative to its earnings before interest, taxes, depreciation, and amortization due to the loss-making status. The stock trades between a 52-week high of $4.50 and a 52-week low of $1.26, and given the current market capitalization of $9.71M and typical share structures for this sector, the price sits within this range, reflecting high volatility. The beta value is 2.33, indicating that the stock price is expected to fluctuate with significantly higher volatility than the broader market, amplifying both potential gains and losses relative to the S&P 500.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, precluding a direct comparison of growth rates between the two metrics at this specific moment in the company's lifecycle. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all of its earnings, if any, to reinvest into its AI and biotech initiatives rather than distributing income to shareholders. This reinvestment strategy is standard for technology firms with negative earnings, where capital is directed toward research, development, and platform expansion to achieve future scalability. The overall growth and income profile is defined by high risk and a complete absence of current income distribution, with all financial focus directed toward building the underlying technological assets and seeking a path to profitability.